Bergmann, Karl-Christian http://orcid.org/0000-0002-0306-9922
Graessel, Anke http://orcid.org/0000-0001-9670-3269
Raab, Jennifer
Banghard, Werner
Krause, Linda http://orcid.org/0000-0002-8490-5717
Becker, Sylvia
Kugler, Sebastian
Zuberbier, Torsten
Ott, Verena B. http://orcid.org/0000-0002-0514-6469
Kramer, Matthias F. http://orcid.org/0000-0002-3740-4733
Roth‑Walter, Franziska http://orcid.org/0000-0001-5005-9228
Jensen-Jarolim, Erika http://orcid.org/0000-0003-4019-5765
Guethoff, Sonja
Article History
Received: 15 December 2020
Accepted: 6 January 2021
First Online: 22 February 2021
Compliance with ethical guidelines
:
: A. Graessel, J. Raab, W. Banghard, V.B. Ott, M.F. Kramer and S. Guethoff are employees of Allergy Therapeutics/Bencard Allergie GmbH. K.-C. Bergmann reports personal fees for Lectures: ALK, AstraZeneca, Allergopharma, Almirall, Bencard, Chiesi, GSK, HAL, LETI, Lofarma, Mundipharma, Novartis, Sanofi. Non-financial support as Chair of German Pollen Information Service Foundation, personal fees and non-financial support from Consultant physician for ECARF, personal fees and non-financial support from Advisory Board member of AstraZeneca, ECARF, GSK, Robert-Koch-Institute Berlin (Vice chairman Public Health), Sanofi, outside the submitted work. E. Jensen-Jarolim and F. Roth-Walter are inventors on the immunoBON® patent Patent EP 2 894 478 B1, owned by Biomedical International R + D, Vienna, Austria, of which E. Jensen-Jarolim is shareholder. E. Jensen-Jarolim received honoraria for presentations from Allergy Therapeutics, Allergopharma, Bencard, Meda, Roxall, ThermoFisher, and Vifor, and is consultant or in Advisory Boards for Allergy Therapeutics, Vifor Pharma, Sanofi, previously for MediGene, Germany, Novartis, and Dr. Schär (ceased). T. Zuberbier reports personal fees from Bayer Health Care, FAES, Novartis, Henkel, and AstraZeneca. He received fees for talks and personal fees from AbbVie, ALK, Almirall, Astellas, Bayer Health Care Fee, Bencard Allergie GmbH, Berlin Chemie, HAL, Leti, Meda, Menarini, Merck, MSD, Novartis, Pfizer, Sanofi, Stallergenes, Takeda, Teva, UCB Henkel, Kryolan, L’Oréal outside the submitted work. S. Becker, L. Krause and S. Kugler declare that they have no competing interests.
: The study protocol was approved by the Ethics Committee of the Charité Berlin (EA1/314/19). All participants received detailed information from the supervising physician and provided their written informed consent to participate. They also agreed to the processing and storage of their data in accordance with the General Data Protection Regulation. The study was conducted in accordance with the Declaration of Helsinki and in compliance with all federal, regional and local requirements. Informed consent was obtained from all participants. All data provided were pseudonymised to protect the privacy of the patients who participated in the study as mandated by the applicable laws and regulations.